NV-ISACA
15.10.2018 15:37:05 CEST | Business Wire | Press release
With cybersecurity threats continuing to escalate worldwide, the ISACA/CMMI Institute Cybersecurity Culture Report found that just 5 percent of employees think their organization’s cybersecurity culture is as advanced as it needs to be to protect their business from internal and external threats. More than 4,800 business and technology professionals shared their insights in the global research study, conducted via online polling in June 2018. Results were released today at ISACA’s CSX North America cybersecurity conference in Las Vegas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005149/en/
Cybersecurity culture is a workplace culture in which security awareness and behaviors are integrated into everyone’s daily operations, as well as an executive leadership priority. In a threat-ripe environment, an effective cybersecurity culture can help employees understand their roles and responsibilities in keeping their organizations safe and customer data secure. However, just 34 percent of respondents say they understand their role in their organizations’ cyber culture.
Companies must take an all-hands-on-deck approach to counter cyberattack threats, the report summarizes.
“Enlisting the entire workforce to mitigate an enterprise’s cyber risk is an emerging practice,” says Doug Grindstaff II, SVP of Cybersecurity Solutions at CMMI Institute . “We are hearing a lot of feedback about how organizations can move the needle on employee involvement. It’s challenging, but organizations are rightly concerned by the growing sophistication of cyberattacks.”
Widespread employee involvement correlates strongly with the minority of organizations that have achieved strong satisfaction with their cybersecurity culture. Nine in ten employees (92 percent) at these organizations say that their C-level executives share an excellent understanding of the underlying issues, which may be why they loop-in their employees so well; 84 percent of employees at these organizations say they understand their role in cybersecurity.
Other critical findings include:
- Many organizations lack the first—and all-important—step toward a cybersecurity culture: 42 percent of organizations do not have an outlined cybersecurity culture management plan or policy.
- Aligning the entire workforce with the organization’s cybersecurity policies requires significant capital: Organizations that report a significant gap between their current and desired cybersecurity culture are spending just 19 percent of their annual cybersecurity budget on training and tools; organizations that believe their cybersecurity culture is where it is supposed to be are spending more than twice as much (43 percent).
“A key motivator for organizations delaying investing in their cybersecurity cultures is a lack of awareness about the attempted threats and ongoing risks, as well as a lack of awareness about the assets at risk to cybersecurity threats,” said Rob Clyde, NACD Board Leadership Fellow and ISACA Board Chair. “However, individuals tend to underestimate the potential damage and overestimate technology’s ability to limit such incidents. Doing so puts their organizations at serious risk.”
To view the research, visit www.isaca.org/cybersecurity-culture-study .
About ISACA
Nearing its 50th year, ISACA ® (isaca.org ) is a global association helping individuals and enterprises achieve the positive potential of technology. ISACA equips professionals with the knowledge, credentials, education and community to advance their careers and transform their organizations.
Twitter: www.twitter.com/ISACANews
About CMMI ® Institute
A subsidiary of ISACA Enterprises, CMMI Institute (cmmiinstitute.com ) is the global leader in the advancement of best practices in people, process and technology. The Institute provides the tools and support for organizations to benchmark their capabilities and maturity by comparing their operations to best practices and identifying performance gaps.
Twitter: https://twitter.com/CMMI_Institute
View source version on businesswire.com: https://www.businesswire.com/news/home/20181015005149/en/
Contact:
ISACA Emily Van Camp, +1.847.385.7223 evcamp@isaca.org or Kristen Kessinger, +1.847.660.5512 kkessinger@isaca.org
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
